Cell Medica develops, manufactures and markets personalized cellular immunotherapeutics for cancer and infectious diseases.

Cell Medica is committed to improving patients’ lives through the significant therapeutic potential of cellular immunotherapy. Our approach is to apply innovative technologies with the aim of improving the treatment of cancer and immune reconstitution following hematopoietic stem cell transplant.

About Us

Our News

Keep upto date with our regular news and updated on all our research and product launches

Cell Medica team touring the new manufacturing facility in Stevenage

Cell Medica develops, manufactures and markets personalized cellular immunotherapeutics for cancer and infectious diseases.

Read More...

Cell Medica announces the appointment of Kevin Boyle as Chief Financial Officer

Cell Medica develops, manufactures and markets personalized cellular immunotherapeutics for cancer and infectious diseases.

Read More...

Cell Medica announces the appointment of Luis Borges, PhD, as Chief Scientific Officer

Cell Medica develops, manufactures and markets personalized cellular immunotherapeutics for cancer and infectious diseases.

Read More...

Cell Medica announces appointment of industry leader Dr Annalisa Jenkins as Chair

Cell Medica develops, manufactures and markets personalized cellular immunotherapeutics for cancer and infectious diseases.

Read More...

Cell Medica acquires WT1 cancer immunotherapy from Cell and Gene Therapy Catapult

Cell Medica develops, manufactures and markets personalized cellular immunotherapeutics for cancer and infectious diseases.

Read More...

£60 million Series C financing to advance multiple cancer programmes

Cell Medica develops, manufactures and markets personalized cellular immunotherapeutics for cancer and infectious diseases.

Read More...
More News Posts